Volume 19, Number 1—January 2013
Dispatch
Klebsiella pneumoniae Antimicrobial Drug Resistance, United States, 1998–2010
Table 1
Klebsiella pneumoniae antimicrobial drug resistance among inpatients, by year, United States, 1998–2010*
Antimicrobial drug | No. | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | Total change† |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
TET | 80,862 | 14.2 | 14.7 | 14.6 | 13.9 | 14.2 | 13 | 15.6 | 14.8 | 15.6 | 15.2 | 15.3 | 16.4 | 16.7 | 2.5 |
AMK | 232,933 | 0.7 | 0.9 | 0.8 | 0.9 | 1 | 1.1 | 2.1 | 3.7 | 4.9 | 4.6 | 4.9 | 4.6 | 4.5 | 3.8 |
IPM | 259,589 | 0 | 0 | 0 | 0 | 0 | 0 | 0.3 | 0.6 | 0.6 | 1.5 | 3.3 | 3.8 | 4.3 | 4.3 |
GEN | 344,597 | 4.9 | 4.6 | 4.6 | 5.2 | 5.5 | 5.6 | 6.9 | 8.3 | 8.4 | 7.8 | 8.7 | 9.1 | 9.2 | 4.3 |
CPM | 211,134 | 2.1 | 2 | 2.7 | 2.3 | 2.3 | 2.5 | 5.1 | 5.3 | 5.5 | 5.8 | 7.7 | 7.3 | 7.7 | 5.6 |
TMP/SXT | 344,522 | 10.9 | 11 | 10.9 | 10.4 | 10.4 | 10.9 | 13 | 15 | 16.2 | 16.5 | 19.4 | 18.9 | 19.3 | 8.4 |
TZP | 250,554 | 4 | 5.5 | 5.4 | 5.3 | 5.3 | 5.6 | 7.7 | 8.8 | 8.4 | 7.8 | 10.5 | 12 | 12.7 | 8.7 |
TOB | 289,287 | 4.6 | 4.5 | 4.4 | 4.8 | 5.2 | 5.5 | 8 | 9.8 | 11.9 | 10.4 | 13.2 | 13.2 | 13.8 | 9.2 |
CRO | 287,091 | 1.8 | 2.7 | 3.2 | 2.9 | 2.6 | 3.1 | 5.7 | 6.9 | 8.1 | 8.7 | 11.1 | 11.2 | 12.1 | 10.3 |
CIP | 306,348 | 5.5 | 6.1 | 6.5 | 7 | 7.6 | 7.9 | 9.9 | 11.7 | 14.4 | 14.6 | 17 | 16.8 | 16.8 | 11.3 |
CAZ | 248,004 | 5.5 | 6.8 | 7.9 | 7.9 | 7.7 | 7.8 | 11.3 | 13.3 | 12.3 | 12.3 | 15.6 | 15.2 | 17.2 | 11.7 |
ATM | 184,981 | 7.7 | 7.7 | 7.7 | 7.5 | 8 | 7.3 | 11.2 | 12.9 | 12.8 | 12.8 | 16.6 | 16.1 | 22.2 | 14.5 |
*TET, tetracycline; AMK, amikacin; IPM, imipenem; GEN, gentamicin; CPM, cefepime; TMP/SXT, trimethoprim/sulfamethoxazole; TZP, piperacillin/tazobactam; TOB, tobramycin; CRO, ceftriaxone; CIP, ciprofloxacin; CAZ, ceftazidime; ATM, aztreonam.
†Change from 1998 to 2010. p<0.0001 for all antimicrobial agents except tetracycline (p = 0.0745).